Leerink Partnrs Issues Negative Estimate for BMY Earnings

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q3 2025 earnings per share estimates for Bristol Myers Squibb in a research note issued to investors on Wednesday, July 9th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings of $1.67 per share for the quarter, down from their previous estimate of $1.69. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share. Leerink Partnrs also issued estimates for Bristol Myers Squibb's Q4 2025 earnings at $1.65 EPS, FY2028 earnings at $5.57 EPS and FY2029 earnings at $6.07 EPS.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The firm's revenue for the quarter was down 5.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($4.40) earnings per share.

Several other equities research analysts have also recently weighed in on BMY. UBS Group reduced their price target on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. Jefferies Financial Group dropped their target price on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 target price on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Argus raised Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. Finally, Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $57.69.

Bristol Myers Squibb Stock Down 3.1%

BMY stock traded down $1.53 during midday trading on Thursday, hitting $47.00. The stock had a trading volume of 6,580,178 shares, compared to its average volume of 12,839,028. The firm has a market cap of $95.64 billion, a price-to-earnings ratio of 17.60, a price-to-earnings-growth ratio of 1.41 and a beta of 0.36. The business has a 50-day moving average of $47.58 and a two-hundred day moving average of $53.35. Bristol Myers Squibb has a 52-week low of $39.93 and a 52-week high of $63.33. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17.

Institutional Trading of Bristol Myers Squibb

A number of hedge funds and other institutional investors have recently bought and sold shares of BMY. Vanguard Group Inc. grew its position in shares of Bristol Myers Squibb by 0.8% during the first quarter. Vanguard Group Inc. now owns 191,403,004 shares of the biopharmaceutical company's stock worth $11,673,669,000 after purchasing an additional 1,458,488 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Bristol Myers Squibb by 0.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 60,606,905 shares of the biopharmaceutical company's stock valued at $3,696,415,000 after buying an additional 306,430 shares during the last quarter. Capital International Investors boosted its stake in Bristol Myers Squibb by 7.5% during the fourth quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock valued at $2,593,940,000 after buying an additional 3,218,865 shares during the last quarter. Geode Capital Management LLC boosted its stake in Bristol Myers Squibb by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 44,391,247 shares of the biopharmaceutical company's stock valued at $2,505,967,000 after buying an additional 1,187,231 shares during the last quarter. Finally, Norges Bank bought a new position in Bristol Myers Squibb during the fourth quarter valued at approximately $1,989,525,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Buying and Selling

In related news, EVP Samit Hirawat purchased 4,250 shares of Bristol Myers Squibb stock in a transaction on Friday, April 25th. The stock was acquired at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president directly owned 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.09% of the company's stock.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.28%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.